ImmunoPrecise Antibodies expands LENSai Platform, integrating epitope binning to analyze 5,000 sequences without physical materials.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic company, has expanded its LENSai TM Platform, integrating epitope binning to analyze over 5,000 sequences without requiring physical materials. The epitope binning method categorizes monoclonal antibodies targeting specific proteins, helping scientists determine similar binding sites. This innovation matches the results of classical wet lab binning.